PRF Technologies Ltd.

PRF Technologies Ltd. is a diversified innovation company based in Tel Aviv-Yafo, Israel, focusing on specialty pharmaceutical therapies and AI-driven energy analytics. The company's mission is to improve patient outcomes through advanced drug-delivery technologies and to optimize energy performance using artificial intelligence. It was formerly known as PainReform Ltd. and officially changed its name in January 2026 to reflect its expanded strategic focus.

In the pharmaceutical sector, PRF Technologies develops reformulation and sustained-release drug-delivery technologies. Key products include PRF-110, an oil-based solution designed for localized and extended post-operative pain relief, currently undergoing Phase 3 clinical trials. Another significant product is OcuRing-K, a bio-erodible sustained-release implant intended to manage pain and inflammation following cataract surgery. Beyond healthcare, the company operates the DeepSolar platform, which provides AI-driven solutions for solar asset owners and operators to monitor, forecast, and optimize energy performance.

PRF Technologies Ltd. is publicly traded on NASDAQ under the ticker PRFX. Recent developments include the advancement of its DeepSolar Predict™ platform towards commercial launch and the FDA clearance of an Investigational New Drug (IND) application for the OcuRing™-K Phase II clinical trial. The company also reported expanded preclinical results for PRF-110, demonstrating comparable analgesic efficacy to an approved benchmark. Dr. Ehud Geller serves as the Executive Chairman, with Mr. Efraim Cohen-Arazi as the Interim CEO.